AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Noxopharm limited asx nox
Australian Healthcare Players in Race to Develop COVID-19 Treatment – NOX, MSB, DXB
June 30, 2020 01:28 PM AEST| By Team Kalkine MediaThe outbreak of coronavirus pandemic has driven the healthcare sector into spotlight, initiating a race to develop preventive and therapeutic interventions. The severity of COVID-19 can be comprehended by over 10 million cases and more than 500k de.....
Noxopharm to Initiate COVID-19 Trial Program in Europe, Continues Discussions with FDA
June 22, 2020 04:03 PM AEST| By Team Kalkine MediaAustralian clinical stage drug developer, Noxopharm Limited (ASX:NOX) notified in its latest update the commencement of NOXCOVID clinical trial program in Europe, focusing on safety and proof-of principle endpoints of Veyonda® as a potential tr.....
Noxopharm’s potential COVID-19 treatment - Lodges pre-IND Submission with FDA for Veyonda® Clinical Trial
May 25, 2020 01:02 PM AEST| By Team Kalkine MediaMarking a step forward, clinical-stage drug development company Noxopharm (ASX:NOX) has lodged a pre-IND (Investigational New Drug) submission with the U.S. Food and Drug Administration (FDA) for a Veyonda® clinical trial in COVID-19 (SARS-C...
Noxopharm Confirms Abscopal Responses in DARRT-1 Patients
May 06, 2020 02:19 PM AEST| By Team Kalkine MediaBiotech company Noxopharm Limited (ASX:NOX) possesses an exciting new potential treatment for end-stage prostate cancer as suggested by the latest radiographic review of DARRT-1 clinical study, supporting the Company’s belief in the anti-cancer...
Noxopharm’s Breakthrough in Brain Cancer Program; Second Pipeline Drug Program Confirmed
April 30, 2020 03:42 PM AEST| By Team Kalkine MediaIn a new development, clinical-stage oncology drug development player Noxopharm Limited (ASX:NOX) has confirmed that an isoflavonoid drug candidate has passed the proof-of-principle test for its brain cancer program in laboratory studies, paving the...
Noxopharm Aims to Test Veyonda® Against COVID-19, US FDA Approval To be Sought for Clinical Study
April 22, 2020 01:59 PM AEST| By Team Kalkine MediaClinical-stage Australian oncology drug development player Noxopharm (ASX:NOX) has revealed that the active ingredient in Veyonda® - idronoxil, blocks the STING (Stimulator of Interferon Genes) signalling pathway associated with the type of cellu...
Noxopharm Investigating Idronoxil’s Potential in COVID-19 Treatment
April 06, 2020 01:49 PM AEST| By Team Kalkine MediaAustralian oncology drug development company Noxopharm (ASX:NOX), along with the Hudson Institute of Medical Research in Melbourne, has identified anti-inflammatory properties of idronoxil, consistent with reducing a ‘cytokine storm’ whic...
Noxopharm registered drug Veyonda® Granted 1st Allowed Patent Application, Advancing on Commercialisation Strategy
March 26, 2020 12:55 PM AEDT| By Team Kalkine MediaAustralian clinical stage drug development company Noxopharm Limited (ASX:NOX) recently announced a significant milestone, that its potentially transformative anti-cancer drug candidate Veyonda® has been awarded first allowed patent application (...
Noxopharm’s Veyonda® Granted IND for Sarcoma Patients.
February 25, 2020 06:53 PM AEDT| By Team Kalkine MediaLatest LuPIN Trial Interim Results and an Alliance with Oncology Services Provider, GenesisCare Further Enhance Veyonda®’s Potential Commercial and Shareholder Value Australian clinical-stage drug development company Noxopharm Limite...
Noxopharm Seeks to Bring Veyonda® to Market as a First-in-class Drug to Boost the Effectiveness of Radiation Therapy in Prostate Cancer
February 10, 2020 02:58 PM AEDT| By Team Kalkine MediaNoxopharm Limited (ASX:NOX), an Australian clinical stage biotechnology company with its focus on oncology, is known for developing a novel, potentially transformative and industry disruptive cancer drug treatment using its lead candidate, Veyonda&re...
Advertise your brand on Kalkine Media